Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats

REFERENCES

• El-Serag HB: Hepatocellular carcinoma. N Engl J Med 365, 1118–1127, 2011.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Maida M, Genco C, Antonucci M, and Cammà C: Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 39, 374–383, 2012.
   PubMed Web of Science ®Google Scholar
• Kwon H and Lok AS: Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther 16, 787–795, 2011.
   PubMed Web of Science ®Google Scholar
• Michielsen P and Ho E: Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 74, 4–8, 2011.
   PubMed Web of Science ®Google Scholar
• Torres DM and Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 32, 30–38, 2012.
   PubMed Web of Science ®Google Scholar
• Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, et al.: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128, 2436–2443, 2011.
   PubMed Web of Science ®Google Scholar
• Szabo G and Lippai D: Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis 30, 243–248, 2012.
   PubMed Web of Science ®Google Scholar
• Alison MR, Nicholson LJ, and Lin WR: Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 185, 135–148, 2011.
   PubMedGoogle Scholar
• Zanoli P and Zavatti M: Pharmacognostic and pharmacological profile of Humulus lupulus L. J Ethnopharmacol 116, 383–396, 2008.
   PubMed Web of Science ®Google Scholar
• Desai A, Konda VR, Darland G, Austin M, Prabhu KS, et al.: META060 inhibits multiple kinases in the NF-kappaB pathway and suppresses LPS-mediated inflammation in vitro and ex vivo. Inflamm Res 58, 229–234, 2009.
   PubMed Web of Science ®Google Scholar
• Konda VR, Desai A, Darland G, Bland JS, and Tripp ML: META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. Arthritis Rheum 62, 1683–1692, 2010.
   PubMed Web of Science ®Google Scholar
• Sia D and Villanueva A: Signaling pathways in hepatocellular carcinoma. Oncology 81(Suppl 1), 18–23, 2011.
   PubMed Web of Science ®Google Scholar
• Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, and Dimitriadis G: Pathways and targets in hepatocellular carcinoma. Expert Rev Anticancer Ther 10, 1347–1357, 2012
   Web of Science ®Google Scholar
• Luedde T and Schwabe RF: NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8, 108–118, 2011.
   PubMed Web of Science ®Google Scholar
• He G and Karin M: NF-κB and STAT3: key players in liver inflammation and cancer. Cell Res 21, 159–168, 2011.
   PubMed Web of Science ®Google Scholar
• Staudt LM: Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 1, a000109, 2010.
   Web of Science ®Google Scholar
• Huang KW, Huang Y-C, Tai K-F, Chen B-H, Lee P-H, et al.: Dual therapeutic effects of interferon-α gene therapy in a rat hepatocellular carcinoma model with liver cirrhosis. Molecular Therapy 16, 1681–1687, 2008.
   PubMed Web of Science ®Google Scholar
• Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, and Tergaonkar V: Multifaceted link between cancer and inflammation. Biosci Rep 32, 1–15, 2012.
   PubMed Web of Science ®Google Scholar
• Shaulian E: AP-1—The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 22, 894–899, 2010.
   PubMed Web of Science ®Google Scholar
• Schonthaler HB, Guinea-Viniegra J, and Wagner EF: Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis 70(Suppl. 1), i109–i112, 2011.
   PubMed Web of Science ®Google Scholar
• Leonardi GC, Candido S, Cervello M, Nicolosi D, Raiti F, et al.: The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 40, 1733–1747, 2012.
   PubMed Web of Science ®Google Scholar
• Newell P, Villanueva A, Friedman SL, Koike K, and Llovet JM: Experimental models of hepatocellular carcinoma. J Hepatol 48, 858–879, 2008.
   PubMed Web of Science ®Google Scholar
• Vroegrijk IO, van Diepen JA, van den Berg SA, Romijn JA, Havekes LM, et al.: META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse. Nutrition 29, 276–283, 2013.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103, 10544–10551, 2006.
   PubMed Web of Science ®Google Scholar
• Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, et al.: Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36, 1306–1311, 2004.
   PubMed Web of Science ®Google Scholar
• Neergheen VS, Bahorun T, Taylor EW, Jen LS, and Aruoma OI: Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 5, 229–241, 2010.
   Web of Science ®Google Scholar
• Hall AJ, Babish JG, Darland GK, Carroll BJ, Konda VR, et al.: Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops. Phytochemistry 69, 1534–1547, 2008.
   PubMed Web of Science ®Google Scholar
• Holick MF, Lamb JJ, Lerman RH, Konda VR, Darland G, et al.: Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. J Bone Miner Metab 28, 342–350, 2010.
   PubMed Web of Science ®Google Scholar
• Lamb JJ, Holick MF, Lerman RH, Konda VR, Minich DM, et al.: Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome. Nutr Res 31, 347–355, 2011.
   PubMed Web of Science ®Google Scholar
• Desai A, Darland G, Bland JS, Tripp ML, and Konda VR: META060 attenuates TNF-α-activated inflammation, endothelial-monocyte interactions, and matrix metalloproteinase-9 expression, and inhibits NF-κB and AP-1 in THP-1 monocytes. Atherosclerosis 223, 130–136, 2012.
   PubMed Web of Science ®Google Scholar
• Konda VR, Desai A, Darland G, Bland JS, and Tripp ML: Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation. J Inflamm (Lond) 6, 26, 2009.
   PubMed Web of Science ®Google Scholar
• Vainer GW, Pikarsky E, and Ben-Neriah Y: Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett 267, 182–188, 2008.
   PubMed Web of Science ®Google Scholar
• Alayev A and Holz MK: mTOR signaling for biological control and cancer. J Cell Physiol 228, 1658–1664, 2013.
   PubMed Web of Science ®Google Scholar
• Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, et al.: Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol 71, 1297–1307, 2013.
   PubMed Web of Science ®Google Scholar
• Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, et al.: Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 11, 85, 2012.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Chiang DY, Newell P, Peix J, Thung S, et al.: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972–1983, 2008.
   PubMed Web of Science ®Google Scholar